| Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade DT Le, JN Durham, KN Smith, H Wang, BR Bartlett, LK Aulakh, S Lu, ... Science 357 (6349), 409-413, 2017 | 5986 | 2017 |
| Neoadjuvant PD-1 blockade in resectable lung cancer PM Forde, JE Chaft, KN Smith, V Anagnostou, TR Cottrell, MD Hellmann, ... New England Journal of Medicine 378 (21), 1976-1986, 2018 | 1893 | 2018 |
| Evolution of neoantigen landscape during immune checkpoint blockade in non–small cell lung cancer V Anagnostou, KN Smith, PM Forde, N Niknafs, R Bhattacharya, J White, ... Cancer discovery 7 (3), 264-276, 2017 | 824 | 2017 |
| Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC) TR Cottrell, ED Thompson, PM Forde, JE Stein, AS Duffield, ... Annals of Oncology 29 (8), 1853-1860, 2018 | 375 | 2018 |
| Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers JX Caushi, J Zhang, Z Ji, A Vaghasia, B Zhang, EHC Hsiue, BJ Mog, ... Nature 596 (7870), 126-132, 2021 | 278 | 2021 |
| Dynamics of tumor and immune responses during immune checkpoint blockade in non–small cell lung cancer V Anagnostou, PM Forde, JR White, N Niknafs, C Hruban, J Naidoo, ... Cancer research 79 (6), 1214-1225, 2019 | 257 | 2019 |
| Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer V Anagnostou, N Niknafs, K Marrone, DC Bruhm, JR White, J Naidoo, ... Nature cancer 1 (1), 99-111, 2020 | 165 | 2020 |
| The mutation-associated neoantigen functional expansion of specific T cells (MANAFEST) assay: a sensitive platform for monitoring antitumor immunity L Danilova, V Anagnostou, JX Caushi, JW Sidhom, H Guo, HY Chan, ... Cancer immunology research 6 (8), 888-899, 2018 | 140 | 2018 |
| Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer JE Reuss, V Anagnostou, TR Cottrell, KN Smith, F Verde, M Zahurak, ... Journal for immunotherapy of cancer 8 (2), 2020 | 131 | 2020 |
| Redundant innate and adaptive sources of IL17 production drive colon tumorigenesis F Housseau, S Wu, EC Wick, H Fan, X Wu, NJ Llosa, KN Smith, A Tam, ... Cancer research 76 (8), 2115-2124, 2016 | 126 | 2016 |
| Compartmental analysis of T-cell clonal dynamics as a function of pathologic response to neoadjuvant PD-1 blockade in resectable non–small cell lung cancer J Zhang, Z Ji, JX Caushi, M El Asmar, V Anagnostou, TR Cottrell, ... Clinical Cancer Research 26 (6), 1327-1337, 2020 | 105 | 2020 |
| Metabolic programs define dysfunctional immune responses in severe COVID-19 patients EA Thompson, K Cascino, AA Ordonez, W Zhou, A Vaghasia, ... Cell reports 34 (11), 2021 | 101 | 2021 |
| Functional characterization of CD4+ T cell receptors crossreactive for SARS-CoV-2 and endemic coronaviruses AG Dykema, B Zhang, BA Woldemeskel, CC Garliss, LS Cheung, ... The Journal of clinical investigation 131 (10), 2021 | 76 | 2021 |
| Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial PM Forde, V Anagnostou, Z Sun, SE Dahlberg, HL Kindler, N Niknafs, ... Nature medicine 27 (11), 1910-1920, 2021 | 74 | 2021 |
| The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability NG LaRocca, LD Hudson, R Rudick, D Amtmann, L Balcer, R Benedict, ... Multiple Sclerosis Journal 24 (11), 1469-1484, 2018 | 55 | 2018 |
| Intratumoral adaptive immunosuppression and type 17 immunity in mismatch repair proficient colorectal tumors NJ Llosa, B Luber, AJ Tam, KN Smith, N Siegel, AH Awan, H Fan, T Oke, ... Clinical Cancer Research 25 (17), 5250-5259, 2019 | 52 | 2019 |
| Selective Induction of CTL Helper Rather Than Killer Activity by Natural Epitope Variants Promotes Dendritic Cell–Mediated HIV-1 Dissemination RB Mailliard, KN Smith, RJ Fecek, G Rappocciolo, EJM Nascimento, ... The Journal of Immunology 191 (5), 2570-2580, 2013 | 50 | 2013 |
| Persistent mutation burden drives sustained anti-tumor immune responses N Niknafs, A Balan, C Cherry, K Hummelink, K Monkhorst, XM Shao, ... Nature medicine 29 (2), 440-449, 2023 | 48 | 2023 |
| Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy M Hwang, JV Canzoniero, S Rosner, G Zhang, JR White, Z Belcaid, ... Journal for immunotherapy of cancer 10 (6), 2022 | 43 | 2022 |
| Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1 KN Smith, NJ Llosa, TR Cottrell, N Siegel, H Fan, P Suri, HY Chan, H Guo, ... Journal for immunotherapy of cancer 7, 1-8, 2019 | 43 | 2019 |
